BiotechTube
Interactome Biotherapeutics

Interactome Biotherapeutics

Cambridge, United States· Est.
interactomebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Interactome Biotherapeutics is a private, pre-clinical stage biotech leveraging a next-generation Secretome platform derived from progenitor cells and exosomes. The company's core technology, Nanovate™, aims to harness the complex signaling of extracellular vesicles and proteins to address significant unmet needs in nerve injury, rare diseases, and oncology. With a recently formed Scientific Advisory Board and an option agreement with Oxford University Innovation, Interactome is building its scientific and partnership foundation to advance its therapeutic pipeline.

NeurologyOncologyCardiologyRare Disease

Technology Platform

Nanovate™ platform producing a next-generation, multi-targeted Secretome containing hundreds of biologically active proteins, factors, and exosomes derived from progenitor cells, designed to modulate inflammation and promote cellular regeneration and recovery.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The platform's multi-targeted approach addresses complex diseases like nerve injury and degenerative conditions where single-pathway drugs often fail, tapping into large, underserved markets in neurology and rare diseases.
Strategic partnerships with academic institutions like Oxford provide access to cutting-edge research and can de-risk early development.

Risk Factors

Major scientific risks include the challenge of consistently manufacturing and characterizing a complex natural Secretome product and demonstrating a clear mechanism of action to regulators.
As a pre-revenue, private company, it faces significant financial risk and is dependent on raising capital to advance its costly preclinical and clinical development.

Competitive Landscape

Interactome operates in the competitive and rapidly evolving fields of extracellular vesicle therapeutics and regenerative medicine, facing competition from both well-funded biotech startups and large pharmaceutical companies exploring similar modalities. Its differentiation hinges on the specific composition and purported superiority of its proprietary Secretome platform and its ability to secure strong intellectual property.

More companies in Biologics / Biosimilars →More companies in United States →